DSKYF DAIICHI SANKYO COMPANY LIMITED
- 38.560
- 0.0000.00%
DAIICHI SANKYO COMPANY LIMITED News
Merck, Daiichi Post Mid-stage Data for Novel Lung Cancer Drug
Jefferies Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Raises Target Price to $53.04
Jefferies analyst Stephen Barker maintains $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ with a buy rating, and adjusts the target price from $45.63 to $52.27.According to TipRanks data, the analyst
Citi Initiates DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Announces Target Price $48.4
Citi analyst Hidemaru Yamaguchi initiates coverage on $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ with a buy rating, and sets the target price at $48.49.According to TipRanks data, the analyst has a
Jefferies Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Cuts Target Price to $45.63
Jefferies analyst Stephen Barker maintains $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ with a buy rating, and adjusts the target price from $45.72 to $45.33.According to TipRanks data, the analyst
J.P. Morgan Maintains DAIICHI SANKYO COMPANY LIMITED(DSKYF.US) With Buy Rating, Raises Target Price to $47.41
J.P. Morgan analyst Seiji Wakao maintains $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ with a buy rating, and adjusts the target price from $42.97 to $47.According to TipRanks data, the analyst has a
Merck, Daiichi Sankyo Expand Cancer Drug Deal
Daiichi Sankyo Non-GAAP EPS of Yen 44.57, Revenue of Yen 436.19B
DAIICHI SANKYO COMPANY LIMITED To Go Ex-Dividend On September 27th, 2024 With 0.264 USD Dividend Per Share
July 9th (Eastern Time) - $DAIICHI SANKYO COMPANY LIMITED(DSKYF.US)$ is trading ex-dividend on September 27th, 2024.Shareholders of record on September 30th, 2024 will receive 0.264 USD dividend per
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Merck, Daiichi Lung Cancer Therapy Rejected in U.S.
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Reported Earlier, Daiichi Sankyo And AstraZeneca's ENHERTU Shows Progression-Free Survival To 13.2 Months In HR Positive, HER2 Low Metastatic Breast Cancer
The overall survival (OS) data for the TROP2 ADC drug DS-1062 (datopotamab deruxtecan), developed by AstraZeneca in collaboration with Daiichi Sankyo, did not meet statistical assumptions but was numerically beneficial to the drug in clinical trials. Alth
The overall survival (OS) data for the TROP2 ADC drug DS-1062 (datopotamab deruxtecan), developed by AstraZeneca in collaboration with Daiichi Sankyo, did not meet statistical assumptions but was numerically beneficial to the drug in clinical trials. Although the Tropion-Lung01 clinical study did not reach the primary OS endpoint, the application for marketing was supported by reaching the primary study endpoint in progression-free survival (PFS). Currently, the drug's marketing application is being reviewed by global regulators such as the US and the European Union. Industry insiders think even though OS is the “gold standard” for drug review
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Daiichi Sankyo/AstraZeneca (AZN.US) launches phase III clinical first-line treatment for EGFR mutation NSCLC in China
On May 27, according to the CDE clinical trial registration and information disclosure platform, Daiichi Sanko/AstraZeneca (AZN.US) registered on the platform to launch a new phase III clinical tropion-Lung14 study with dATO-DXD (DS-1062A/dedabotumab) to first-line treatment of patients with locally advanced or metastatic NSCLC positive EGFR mutations (registration number: CTR20241813).
The backstage Nikkei Average started with 119 yen depreciation, and Daiichi Sankyo, Nintendo, etc. fell
[Nikkei Stock Average, TOPIX (table)] Nikkei Average; 38780.55; -119.47TOPIX; 2762.23; -4.13 [Backward Closer Overview] The Nikkei Average in the back was 38780.55 yen, 119.47 yen lower than the previous day, and started at almost the same level as the advance draw (38783.27 yen). Nikkei 225 futures during lunchtime fit well in the 38760 yen to 38840 yen range. Dollar/yen is 1 dollar = 156.60-70 yen, and yen appreciates by about 20 yen from around 9:00 a.m.
AstraZeneca, Daiichi Sankyo's Lung Cancer Drug Shows Mixed Results in Late-stage Trial
Datopotamab Deruxtecan Showed Clinically Meaningful Overall Survival Improvement Versus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Double Good News For AstraZeneca's Breast Cancer Drugs
Daiichi Sankyo And AstraZeneca's Shows Statistically Significant And Clinically Meaningful Improvement In HR+, HER2 Low Breast Cancer: DESTINY-Breast06 Trial Results
Analysis
Price Target
No Data
